Skip to main content

1 Result(s)

within Ann-Li Cheng Remove this filter Cancer Research Remove this filter

and

  1. Article

    Open Access

    Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

    This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET over...

    Baek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, Tae-You Kim… in British Journal of Cancer (2021)

    Download PDF (536 KB) View Article